Last Update 05 Feb 26

Fair value Increased 0.05%

IONS: Triglyceride Market Shift And SHTG Launch Progress Will Shape Outlook

Analysts nudged their fair value target for Ionis Pharmaceuticals slightly higher to about US$90.67 from roughly US$90.63, citing updated assumptions around discount rates, revenue growth, profit margins and a higher future P/E, along with recent Street research that highlights evolving expectations for the triglyceride lowering market where Ionis and Arrowhead both participate.

Analyst Commentary

Bullish Takeaways

Bullish analysts view the refreshed fair value near US$90.67 as consistent with a company that could justify a higher future P/E, reflecting confidence in execution rather than only near term trading sentiment.
Street research on the triglyceride lowering space points to a growing focus on familial chylomicronemia syndrome and severe hypertriglyceridemia, which bullish analysts see as supportive for Ionis as one of the key participants in this segment.
The recent US$48 price target cited for Arrowhead, tied to the FDA approval of Redemplo, signals to some investors that this treatment area is gaining more attention. Bullish analysts interpret this as validation that the market for triglyceride lowering therapies is meaningful for Ionis as well.
Supportive commentary around pricing for Redemplo is viewed by bullish analysts as a helpful reference point when thinking about revenue potential and valuation frameworks applied to Ionis within the same therapeutic category.

Bearish Takeaways

Bearish analysts highlight that as both Ionis and Arrowhead move from an FCS focus to the broader severe hypertriglyceridemia opportunity, competition could weigh on future pricing power and share capture assumptions used in valuation work.
The description of Redemplo's approval as a "best case" label scenario leads cautious analysts to question whether Ionis can secure similarly favorable regulatory outcomes, which could affect revenue and margin expectations embedded in current fair value estimates.
While some research points to constructive pricing for Redemplo, bearish analysts warn that payer responses and real world utilization are uncertain, which may introduce execution risk for Ionis as the triglyceride lowering market develops.
Given the close read across from Arrowhead's progress, cautious analysts argue that any slowdown or setbacks in this treatment area for peers could cause investors to reassess growth and profit margin assumptions for Ionis as well.

What's in the News

Ionis highlighted 2025 results and 2026 milestones, including US$105 million in preliminary 2025 U.S. net sales for TRYNGOLZA as the first FDA approved treatment for familial chylomicronemia syndrome, with a business update scheduled at the 44th Annual J.P. Morgan Healthcare Conference on January 13 at 8:15am PT (company announcement).
The company outlined plans for olezarsen, including a potential approval and launch for severe hypertriglyceridemia, a submitted U.S. sNDA following Breakthrough Therapy Designation, and Phase 3 data showing up to 72% placebo adjusted fasting triglyceride reduction and an 85% reduction in acute pancreatitis events, along with updated annual peak net sales guidance to more than US$2b (company announcement).
Ionis reported continued early momentum for DAWNZERA, its RNA targeted therapy for hereditary angioedema, with prescriptions across all patient segments, more repeat prescribers, and expectations for EMA approval and launch in the first quarter of 2026 after prior U.S. FDA approval (company announcement).
Zilganersen for Alexander disease received FDA Breakthrough Therapy designation, supported by a pivotal study in 54 participants where the 50 mg dose led to statistically significant and clinically meaningful stabilization in gait speed and showed consistent benefits across multiple secondary endpoints, with a U.S. Expanded Access Program already underway and an NDA submission planned in the first quarter of 2026 (company announcements).
The FDA granted Breakthrough Therapy designation to olezarsen in adults with severe hypertriglyceridemia, based on Phase 3 CORE and CORE2 data showing up to 72% placebo adjusted triglyceride reductions, 85% fewer acute pancreatitis events and nearly 90% of treated patients reaching triglyceride levels below 500 mg/dL, with a supplemental NDA submission to the FDA planned by year end (company announcements).

Valuation Changes

Fair Value: Adjusted slightly higher from about US$90.63 to roughly US$90.67 per share, reflecting updated model inputs.
Discount Rate: Moved modestly from around 7.35% to about 7.37%, which can affect how future cash flows are translated into today’s value.
Revenue Growth: Ticked from roughly 21.26% to about 21.10%, indicating a marginally lower growth assumption in the valuation model.
Net Profit Margin: Shifted from around 4.95% to about 4.66%, suggesting slightly leaner profitability assumptions in future years.
Future P/E: Increased from roughly 224.56x to about 240.00x, pointing to a higher valuation multiple applied to Ionis in the updated analysis.

Expanding into larger patient populations and strong physician acceptance position Ionis for substantial market share gains and sustained top-line growth.
Strategic partnerships, growing royalties, and a competitive edge in rare disease commercialization enhance financial resilience and support margin expansion.
Expanding into broader indications and dependence on key late-stage assets heighten pricing pressures, regulatory risks, and limit revenue and margin growth amid market and partner challenges.

Catalysts

About Ionis Pharmaceuticals

A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.What are the underlying business or industry changes driving this perspective?

The rapid revenue growth and positive launch trajectory for Tryngolza in familial chylomicronemia syndrome (FCS), along with the imminent launch of Donidalorsen for HAE and multiple late-stage pipeline assets reading out or launching by 2027, are set to drive sustained, stepwise increases in top-line revenue and operating leverage as Ionis transitions from R&D-heavy to commercial-stage.
Expanding addressable patient populations-from rare diseases to larger segments like severe hypertriglyceridemia (sHTG)-combined with favorable physician feedback and significant unmet need, position Ionis to capture substantial market share and revenue growth from trends tied to the rise in chronic disease and an aging population.
Greater acceptance of RNA-targeted and antisense oligonucleotide (ASO) therapies among physicians, regulators, and payors, demonstrated by positive reimbursement outcomes, coverage expansions, and robust adoption, supports Ionis' potential to improve gross and net margins over time as its innovative therapies become increasingly mainstream.
Ionis' growing stream of high-margin royalty and milestone revenues from partnerships (e.g. Biogen, AstraZeneca, Roche), as well as recent substantial out-licensing deals, provides both capital efficiency and financial resilience-helping shore up net margins and reducing risk as operating expenses scale with new launches.
The company's proven ability to rapidly identify, educate, and enroll patients in rare diseases-leveraging omnichannel and specialty networks-signals a first-mover and competitive advantage in precision medicine, supporting revenue durability and premium pricing amid expanding payor willingness to reimburse high-value, personalized therapies.

Ionis Pharmaceuticals Earnings and Revenue Growth

Ionis Pharmaceuticals Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Ionis Pharmaceuticals's revenue will grow by 16.7% annually over the next 3 years.
Analysts are not forecasting that Ionis Pharmaceuticals will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Ionis Pharmaceuticals's profit margin will increase from -28.4% to the average US Biotechs industry of 16.1% in 3 years.
If Ionis Pharmaceuticals's profit margin were to converge on the industry average, you could expect earnings to reach $241.3 million (and earnings per share of $1.48) by about September 2028, up from $-268.2 million today.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 56.5x on those 2028 earnings, up from -35.9x today. This future PE is greater than the current PE for the US Biotechs industry at 15.5x.
Analysts expect the number of shares outstanding to grow by 0.95% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.98%, as per the Simply Wall St company report.

Ionis Pharmaceuticals Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Ionis faces a significant risk of revenue compression as it expands Olezarsen from a rare-disease (FCS) to a broader (sHTG) indication, with management openly discussing that a price reduction will be necessary to address the much larger patient populations-potentially leading to a step-down in average net price and limiting long-term margin growth and earnings expansion.
The company's increasing reliance on a few late-stage assets and upcoming FDA approvals (notably for Donidalorsen and Olezarsen in sHTG) highlights high regulatory and execution risk: setbacks or delays in pivotal data (e.g., insufficient acute pancreatitis outcomes, ambiguity around meaningful endpoints, or label negotiations) could disrupt the launch cadence and result in "lumpy" or stagnating revenue and net income.
Slowdown in new patient identification beyond "low hanging fruit" populations (e.g., initial trial participants or previously diagnosed rare disease patients) suggests that longer-term growth in rare indications like FCS may be constrained by diagnosis rates and market penetration challenges, dampening the sustainability of revenue momentum.
Ionis admits it is not currently building out ex-U.S. infrastructure and will continue to rely on third-party partners (e.g., Sobi, AstraZeneca) for global commercialization, meaning any changes in strategy, performance, or prioritization by these partners could materially impact royalties, milestone revenues, and overall revenue diversification.
Anticipated large-scale pricing negotiations for expanded indications and payer resistance, especially as Ionis targets larger, less severe patient populations, expose the company to global drug pricing pressures and reimbursement complexities, elevating the risk that gross-to-net realization and ultimate revenue growth may fall short of expectations as biosimilars, generics, or competitive modalities (such as CRISPR and new RNA therapies) emerge.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $68.346 for Ionis Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $96.0, and the most bearish reporting a price target of just $43.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $1.5 billion, earnings will come to $241.3 million, and it would be trading on a PE ratio of 56.5x, assuming you use a discount rate of 7.0%.
Given the current share price of $60.49, the analyst price target of $68.35 is 11.5% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Ionis Pharmaceuticals?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Analyst Commentary Highlights Ionis Pharmaceuticals’ Upward Price Target and Valuation Amid Key Clinical Wins